STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”